Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

IKS03 in pazienti con linfomi non-Hodgkin a cellule B avanzati

2 novembre 2026 aggiornato da: Iksuda Therapeutics Ltd.

Uno studio di fase 1 di aumento ed espansione della dose di coorte per determinare la sicurezza, la tolleranza, la dose massima tollerata e l'attività antineoplastica preliminare di IKS03 in pazienti con linfomi non Hodgkin a cellule B avanzati (NHL)

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The study will consist of 2 parts: dose-escalation (Part I) and dose-expansion (Part II). The dose-escalation part (Part I) of the study is to evaluate the safety and tolerability of increasing dose levels of IKS03 to establish a recommended Phase 2 dose (RP2D); and the dose-expansion part (Part II) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of IKS03 at the RP2D.

Tipo di studio

Interventistico

Iscrizione (Stimato)

140

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

  • Australia
    • New South Wales
      • Westmead, New South Wales, Australia, 2145
        • Reclutamento
        • Westmead Hospital
        • Investigatore principale:
          • Amanda Johnston, MD
    • South Australia
      • Adelaide, South Australia, Australia
        • Reclutamento
        • Royal Adelaide Hospital
        • Contatto:
          • Pratyush Giri, MBBS
        • Investigatore principale:
          • Pratyush Giri, MBBS
    • Tasmania
      • Hobart, Tasmania, Australia, 7000
        • Reclutamento
        • Royal Hobart Hospital
        • Investigatore principale:
          • Rosemary Harrup, MD
    • Western Australia
      • Perth, Western Australia, Australia
        • Reclutamento
        • Linear Clinical Research
        • Contatto:
          • Katharine Lewis, MD
        • Investigatore principale:
          • Katharine Lewis, MD
  • Canada
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Reclutamento
        • Jewish General Hospital
        • Investigatore principale:
          • Sarit Assouline, MD
        • Contatto:
          • Sarit Assouline, MD
  • Italia
      • Candiolo, Italia
        • Reclutamento
        • Istituto Nazionale Oncologico Candiolo
        • Contatto:
          • Umberto Vitolo, M.D.
        • Investigatore principale:
          • Umberto Vitolo, M.D.
      • Milan, Italia
        • Reclutamento
        • Istituto Europeo di Oncologia
        • Contatto:
          • Enrico Derenzini, M.D.
        • Investigatore principale:
          • Enrico Derenzini, M.D.
      • Milan, Italia
        • Reclutamento
        • Istituto Europeo Clinico Humanitas
        • Contatto:
          • Carmelo Carlo-Stella, M.D.
        • Investigatore principale:
          • Carmelo Carlo-Stella, M.D.
      • Milan, Italia
        • Reclutamento
        • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele
        • Contatto:
          • Andres Jose Maria Ferreri, M.D.
        • Investigatore principale:
          • Andres Jose Maria Ferreri, M.D.
  • Spagna
      • Badalona, Spagna
        • Reclutamento
        • Institut Catala D'Oncologia
        • Contatto:
          • Mireia Franch-Sarto, M.D.
        • Investigatore principale:
          • Mireia Franch-Sarto, M.D.
      • Madrid, Spagna
        • Reclutamento
        • Hospital Universitario Quironsalud Madrid
        • Contatto:
          • Maria del Carmen Martinez-Chamorro, M.D.
        • Investigatore principale:
          • Maria del Carmen Martinez-Chamorro, M.D.
      • Salamanca, Spagna
        • Reclutamento
        • Hospital Clinico Universitario de Salamanca
        • Contatto:
          • Alejandro Martin Garcia-Sancho, M.D.
        • Investigatore principale:
          • Alejandro Martin Garcia-Sancho, M.D.
  • Stati Uniti
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21201
        • Ritirato
        • University of Maryland Baltimore

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Males or females, ≥ 18 years of age

  2. Part I: documented B cell NHL (any subtype except Burkitt lymphoma, Waldenström macroglobulinemia, chronic lymphocytic leukemia); previously confirmed CD19-positive if feasible

  3. Part II: documented B cell NHL (subtypes to be determined); confirmed CD19-positive; possible expansion cohorts may include:

    1. Diffuse large B cell lymphoma (including germinal center B cell type, activated B cell type)
    2. Follicular lymphoma (including duodenal-type follicular lymphoma)
    3. Mantle cell lymphoma
    4. B cell lymphomas not specified

  4. If B cell NHL subtype likely to have bone marrow involvement must be willing to undergo bone marrow biopsy in the event of an on-study complete response to confirm response

  5. NHL that is relapsed, refractory to, or intolerant of existing therapy(ies) with known curative potential, or for which no standard therapy is available; must have received at least 2 prior lines of systemic therapy

  6. Must be in need of systemic treatment and not require immediate cytoreductive therapy

  7. Part I: measurable or non-measurable disease

  8. Part II: measurable disease according to The Revised Criteria/Lugano Classification

  9. Part I: screening tumor biopsy requested, but optional; Part 2: patient must agree to screening tumor biopsy

  10. ECOG performance status 0 or 1

  11. Women of childbearing potential and fertile men agreeing to use two effective methods of contraception (including a highly effective method of contraception); women beginning 2 weeks prior to the first dose, men beginning prior to the first dose, and both continuing until 8 months after the last dose of study drug; male patients must also agree to refrain from sperm donation during this period.

  12. Ability to understand and give written informed consent

Exclusion Criteria:

  1. Women who are pregnant or intending to become pregnant before, during, or within 8 months after the last dose of study drug; women who are breastfeeding

  2. Patients documented to be CD19-negative

  3. Central nervous system (CNS) lymphoma, leptomeningeal infiltration, or spinal cord compression not controlled by prior surgery or radiotherapy; symptoms suggesting CNS involvement

  4. Part 2: History of another malignancy within 2 years, with the exception of:

    1. Treated, non-melanoma skin cancers
    2. Treated carcinoma in situ (e.g., breast, cervix)
    3. Controlled, superficial carcinoma of the urinary bladder
    4. T1a or b prostate carcinoma treated according to standard of care, with PSA within normal limits
    5. Papillary thyroid carcinoma Stage I treated surgically for cure

  5. Any of the following hematologic abnormalities at baseline (transfusion allowed > 5 days previous):

    1. Hemoglobin < 8.0 g/dL
    2. Absolute neutrophil count < 1,000 per mm3
    3. Platelet count < 75,000 per mm3

  6. Any of the following laboratory abnormalities at baseline:

    1. Total bilirubin > 1.5 × upper limit of normal (ULN); > 3 × ULN if with Gilbert's Syndrome
    2. AST or ALT > 3 × ULN; > 5 × ULN if due to hepatic involvement by tumor
    3. Estimated GFR ≤ 60 mL/min corrected for BSA
    4. Albuminuria defined as urine albumin to creatinine ratio < 30 mg/g or < 3 mg/mmol) by spot urine albumin

  7. Any of the following coagulation parameter abnormalities at baseline unless on a stable dose of anticoagulant therapy for a prior thrombotic event:

    1. PT or INR > 1.5 × ULN; > 3× ULN if anticoagulated)
    2. PTT > 1.5 × ULN; > 3× ULN if anticoagulated

  8. Any of the following laboratory abnormalities at baseline aimed at assessing renal function:

    1. Estimated glomerular filtration rate (eGFR) ≤ 60 mL/min, corrected for BSA.
    2. Albuminuria defined as urine albumin to creatinine ratio (UACR) ≥ 45 mg/g or ≥ 4.5 mg/mmol by spot urine albumin

  9. Patients with:

    1. Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks unless adequately treated and stable
    2. Active uncontrolled bleeding or a known bleeding diathesis

  10. Significant cardiovascular disease or condition, including:

    1. Congestive heart failure or angina pectoris requiring therapy
    2. Ventricular arrhythmia requiring therapy or other uncontrolled arrhythmia
    3. Severe conduction disturbance (e.g., 3rd degree heart block)
    4. QTc interval ≥ 480 milliseconds
    5. Left ventricular ejection fraction below the lower limit of normal or < 50% by MUGA scan or echocardiogram
    6. Class III or IV cardiovascular disease according to the New York Heart Association Functional Classification
    7. History of acute coronary syndromes (e.g., MI, unstable angina), coronary angioplasty, stenting, or bypass within 6 months

  11. Significant liver disease, including:

    1. Non-infectious hepatitis
    2. Hepatic cirrhosis (Child-Pugh Class B and Class C)

  12. Significant pulmonary disease or condition, including:

    1. Significant symptomatic COPD, as assessed by the Investigator
    2. History or any current evidence on imaging studies of interstitial lung disease, pulmonary fibrosis
    3. History of pulmonary inflammatory disease, pneumonitis, ARDS
    4. History of pneumonia within 1 month

  13. Significant corneal disease or condition, including history of or current evidence of keratitis

  14. Clinically significant CNS disease or condition including PML, epilepsy, vasculitis, or neurodegenerative disease. Also including TIA or stroke within 6 months

  15. Known HIV infection or AIDS

  16. Active hepatitis B virus or hepatitis C virus infection

  17. Any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38ºC within 2 weeks

  18. Autoimmune disease or condition requiring systemic steroids or other immunosuppressive medications

  19. Unresolved Grade > 1 AE associated with any prior antineoplastic therapy (except persistent Grade 2 alopecia, peripheral neuropathy, decreased hemoglobin, neutropenia, lymphopenia, hypomagnesemia, and/or endocrine end-organ failure being adequately managed by HRT)

  20. Known or suspected hypersensitivity to any of the excipients of formulated study drug

  21. Inadequate recovery from a surgical procedure, or a major surgical procedure within 4 weeks

  22. Any other serious, life-threatening, or unstable preexisting medical condition, including significant organ system dysfunction, or clinically significant laboratory abnormality(ies)

  23. A psychiatric disorder or altered mental status that would preclude understanding of the informed consent process

Drugs and Other Treatments to be Excluded:

  1. Receipt of:

    1. Any CD19-targeted therapy within 4 weeks
    2. Any tumor vaccine within 6 weeks (must have progressed if previously received)

  2. Prior autologous/allogeneic CAR-T therapy if known to be CD19-negative after

  3. Any other antineoplastic agent for the primary malignancy without delayed toxicity within 3 weeks or 5 plasma half-lives, whichever is shortest (except nitrosoureas and mitomycin C within 6 weeks)

  4. Any other investigational treatments within 3 weeks

  5. Drugs known to impair renal function, including:

    1. NSAIDS within 3 days
    2. Aminoglycoside antibiotics, amphotericin B, etc. within 1 week
    3. Bisphosphonates within 1 month

  6. Prior solid organ transplant

  7. Allogeneic HSCT within 6 months, or:

    1. If receiving immunosuppression
    2. If with active evidence of GVHD

  8. Autologous hematopoietic stem cell transplantation (HSCT) within 3 months

  9. Radiotherapy:

    1. To target lesions within 4 weeks unless progression of the lesion has been documented
    2. To non-target lesions within 1 week

  10. Live/live-attenuated vaccines against infectious diseases within 4 weeks

  11. Immunosuppressive or systemic glucocorticoid therapy (> 10 mg prednisone daily or equivalent) within 2 weeks

  12. Prophylactic use of hematopoietic growth factors within 1 week

  13. Herbal therapies and supplements within 2 weeks

  14. Strong inhibitors of cytochrome P450 within 2 weeks

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Dose Escalation Cohort (Part 1)

Each patient will receive repeat doses (by intravenous (IV) infusions) on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Droga: IKS03

IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.
Sperimentale: Dose Expansion: Diffuse-Large B-Cell Lymphoma Participants

Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Droga: IKS03

IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.
Sperimentale: Dose Expansion: Follicular Cell Lymphoma Participants

Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Droga: IKS03

IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.
Sperimentale: Dose Expansion: Mantle Cell Lymphoma Participants

Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Droga: IKS03

IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.
Sperimentale: Dose Expansion: Other B cell lymphoma (B-NHL not otherwise specified [NOS])

Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Droga: IKS03

IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Recommended Phase 2 Dose (Part I)
Lasso di tempo: Up to 20 months

RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data
Up to 20 months
Objective Response Rate (Part II)
Lasso di tempo: up to 42 months

Antineoplastic effects will be assessed by Criteria for Response Assessment: The Lugano Classification (Cheson 2014)
up to 42 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Evaluation of the immunogenicity of IKS03 (Part I and II)
Lasso di tempo: Up to 42 months

Occurrence of ADA measured in serum at selected timepoints during the study
Up to 42 months
Plasma Concentrations of IKS03 (Part I and II)
Lasso di tempo: Up to 42 months

Pharmacokinetic profile will be characterized by concentrations of IKS03
Up to 42 months
Determine recommended Phase 2 dose (RP2D) (Part II)
Lasso di tempo: Up to 42 months

Based on evidence of antitumor activity, acceptable tolerability, evidence of achieving target plasma concentration
Up to 42 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Iksuda Therapeutics Ltd.

Investigatori

  • Direttore dello studio: Debra Wood, MD, Iksuda Therapeutics

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

5 settembre 2023

Completamento primario (Stimato)

1 settembre 2027

Completamento dello studio (Stimato)

1 settembre 2028

Date di iscrizione allo studio

Primo inviato

2 maggio 2022

Primo inviato che soddisfa i criteri di controllo qualità

6 maggio 2022

Primo Inserito (Effettivo)

9 maggio 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • IKS03-01

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi